Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$70.44 +1.3%	$30.17	$4.77 ▼ $75.51	$5.25B	0.56	3.21 million shs	551,629 shs
ADMA ADMA Biologics	$16.99 +0.1%	$18.29	$13.50 ▼ $25.67	$4.05B	0.38	3.53 million shs	3.11 million shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
MRUS Merus	$67.25 +0.5%	$58.88	$33.19 ▼ $67.59	$5.06B	1.09	680,918 shs	338,220 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+1.27%	+0.44%	+612.96%	+1,072.05%	+540.95%
ADMA ADMA Biologics	+0.12%	+2.85%	-3.96%	-13.71%	-3.30%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+2.02%
MRUS Merus	+0.46%	+5.08%	+19.01%	+61.81%	+33.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX Abivax	3.387 of 5 stars	4.6	3.0	0.0	0.0	2.5	0.8	0.6
ADMA ADMA Biologics	4.3991 of 5 stars	3.7	3.0	0.0	0.0	4.0	2.5	3.1
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRUS Merus	2.0935 of 5 stars	3.5	1.0	0.0	0.0	2.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	3.13	Buy	$92.33	31.08% Upside
ADMA ADMA Biologics	3.33	Buy	$27.67	62.84% Upside
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
MRUS Merus	3.09	Buy	$88.50	31.60% Upside

Current Analyst Ratings Breakdown

Latest CALT, ADMA, ABVX, and MRUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	MRUS Merus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$97.00 ➝ $96.00
7/29/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $112.00
7/23/2025	ABVX Abivax	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$74.00
7/23/2025	ABVX Abivax	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$45.00 ➝ $101.00
7/23/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $70.00
7/23/2025	ABVX Abivax	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $101.00
7/23/2025	ABVX Abivax	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$71.00
7/23/2025	ABVX Abivax	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $95.00
7/18/2025	ABVX Abivax	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$33.00
7/18/2025	ABVX Abivax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$0.69 per share	N/A
ADMA ADMA Biologics	$426.45M	9.51	$0.54 per share	31.35	$1.67 per share	10.17
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
MRUS Merus	$56.23M	90.46	N/A	N/A	$11.13 per share	6.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$190.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	$197.67M	$0.86	19.76	24.62	N/A	44.06%	41.01%	28.47%	N/A
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
MRUS Merus	-$215.33M	-$5.50	N/A	N/A	N/A	-685.64%	-50.28%	-42.00%	10/30/2025 (Estimated)

Latest CALT, ADMA, ABVX, and MRUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	ADMA ADMA Biologics	$0.14	$0.15	+$0.01	$0.14	$121.77 million	$121.98 million
8/5/2025	Q1 2025	MRUS Merus	-$1.17	-$2.23	-$1.06	-$2.23	$9.77 million	$8.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	1.29	1.25	1.25
ADMA ADMA Biologics	0.21	5.33	2.78
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
MRUS Merus	N/A	8.39	8.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
ADMA ADMA Biologics	75.68%
CALT Calliditas Therapeutics AB (publ)	2.83%
MRUS Merus	96.14%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
ADMA ADMA Biologics	3.50%
CALT Calliditas Therapeutics AB (publ)	2.20%
MRUS Merus	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	75.55 million	N/A	Not Optionable
ADMA ADMA Biologics	530	238.63 million	230.38 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
MRUS Merus	37	75.63 million	72.84 million	Optionable

CALT, ADMA, ABVX, and MRUS Headlines

Recent News About These Companies

Merus (NASDAQ:MRUS) Sets New 1-Year High - What's Next?

August 15 at 7:08 PM | marketbeat.com

HC Wainwright Comments on Merus' Q3 Earnings (NASDAQ:MRUS)

August 12, 2025 | americanbankingnews.com

What is HC Wainwright's Estimate for Merus Q3 Earnings?

August 11, 2025 | marketbeat.com

Leerink Partnrs Comments on Merus' Q3 Earnings (NASDAQ:MRUS)

August 11, 2025 | marketbeat.com

Merus N.V. (NASDAQ:MRUS) Receives Consensus Recommendation of "Buy" from Brokerages

August 11, 2025 | marketbeat.com

Merus N.V. (NASDAQ:MRUS) Receives Average Rating of "Buy" from Brokerages

August 10, 2025 | americanbankingnews.com

William Blair Issues Pessimistic Outlook for Merus Earnings

August 10, 2025 | americanbankingnews.com

William Blair Issues Pessimistic Estimate for Merus Earnings

August 9, 2025 | marketbeat.com

Merus (NASDAQ:MRUS) Upgraded at HC Wainwright

August 9, 2025 | marketbeat.com

Needham & Company LLC Lowers Merus (NASDAQ:MRUS) Price Target to $96.00

August 7, 2025 | marketbeat.com

We Think Merus (NASDAQ:MRUS) Can Afford To Drive Business Growth

August 7, 2025 | finance.yahoo.com

Merus (NASDAQ:MRUS) Issues Earnings Results

August 6, 2025 | marketbeat.com

Merus to Present at the Canaccord Genuity 45th Annual Growth Conference

August 6, 2025 | globenewswire.com

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

August 5, 2025 | zacks.com

Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update

August 5, 2025 | globenewswire.com

Westfield Capital Management Co. LP Acquires 508,063 Shares of Merus N.V. (NASDAQ:MRUS)

August 5, 2025 | marketbeat.com

Envestnet Asset Management Inc. Makes New $589,000 Investment in Merus N.V. (NASDAQ:MRUS)

August 5, 2025 | marketbeat.com

Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 4, 2025 | globenewswire.com

BIT Capital GmbH Increases Position in Merus N.V. (NASDAQ:MRUS)

August 4, 2025 | marketbeat.com

Merus N.V. (NASDAQ:MRUS) Stock Position Raised by Allianz Asset Management GmbH

August 3, 2025 | marketbeat.com

TD Asset Management Inc Decreases Stock Position in Merus N.V. (NASDAQ:MRUS)

August 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT, ADMA, ABVX, and MRUS Company Descriptions

Abivax NASDAQ:ABVX

$70.44 +0.88 (+1.27%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$70.26 -0.18 (-0.26%)

As of 08/15/2025 07:14 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

ADMA Biologics NASDAQ:ADMA

$16.99 +0.02 (+0.12%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$16.99 0.00 (0.00%)

As of 08/15/2025 07:08 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 08/14/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Merus NASDAQ:MRUS

$67.25 +0.31 (+0.46%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$67.27 +0.02 (+0.03%)

As of 08/15/2025 07:44 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time